BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/6/2018 1:12:00 PM | Browse: 1370 | Download: 1729
 |
Received |
|
2018-04-02 03:22 |
|
Peer-Review Started |
|
2018-04-02 07:10 |
|
First Decision by Editorial Office Director |
|
2018-04-18 02:37 |
|
Return for Revision |
|
2018-04-21 08:49 |
|
Revised |
|
2018-04-21 17:37 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-04-23 05:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-04-23 16:28 |
|
Articles in Press |
|
2018-04-23 16:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-05-04 10:00 |
|
Publish the Manuscript Online |
|
2018-05-06 13:12 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Elia Moreno-Cubero, Robert Sánchez-del-Arco, Julia Peña-Asensio, Eduardo Sanz-de-Villalobos, Joaquín Miquel and Juan Ramón Larrubia |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Gilead Spain & Instituto de Salud Carlos III |
GLD14_00217 |
| Gilead Spain & Instituto de Salud Carlos III |
GLD16_00014 |
| Instituto de Salud Carlos III, Spain & European Regional Development Fund (ERDF), a way of making Europe |
PI12/00130 |
| Instituto de Salud Carlos III, Spain & European Regional Development Fund (ERDF), a way of making Europe |
PI15/00074 |
|
| Corresponding Author |
Juan Ramón Larrubia, MD, MSc, PhD, Senior Lecturer, Staff Physician, Translational Hepatology Unit, Guadalajara University Hospital, University of Alcalá, Donante de Sangre st, Guadalajara E-19002, Spain. juan.larrubia@uah.es |
| Key Words |
CD8; Lamivudine; Nucleos(t)ide analogues; Tenofovir; Chronic hepatitis B; Entecavir; hepatitis B virus; Treatment cessation |
| Core Tip |
Nucleos(t)ide analogue (NA) treatment efficiently suppress hepatitis B virus replication. However, hepatitis B surface antigen loss, the optimal endpoint of NA therapy, is rarely achieved. Thus, a major unmet need in the management of chronic hepatitis B is the definition of earlier and safe treatment stopping points. There is growing clinical evidence that the majority of patients can benefit from this strategy after long-term NA therapy; yet, no criteria that distinguish which cases can safely stop treatment is established. We review here different biomarkers that could serve as a prognostic tool to safely discontinue therapy, focusing on host antiviral immunity. |
| Publish Date |
2018-05-06 13:12 |
| Citation |
Moreno-Cubero E, Sánchez del Arco RT, Peña-Asensio J, Sanz de Villalobos E, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i17/1825.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i17.1825 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
